Directorate Change

GlaxoSmithKline PLC
29 June 2006

Issued - 29 June 2006 London



                         GlaxoSmithKline plc Announces

                        Change to the Board of Directors



GlaxoSmithKline plc (GSK) announces that Dr Daniel Podolsky has been appointed
as a Non-Executive Director and will join the Board of the Company with effect
from 1st July 2006.



Dr Podolsky is Mallinkrodt Professor of Medicine and Chief of Gastroenterology
at Massachusetts General Hospital and Harvard Medical School as well as Chief
Academic Officer of Partners HealthCare System.



In commenting on the new appointment, Sir Christopher Gent, Chairman of GSK,
said:



"I am delighted that Dr Podolsky has agreed to join the Board.  In addition to
fulfilling the usual responsibilities of a non-executive director, Dan will
spend time within our research and development organisation and, with his
experience, will provide valuable insights to scientific developments outside
GSK."



In addition, the Board has appointed Dr Podolsky and Tom de Swaan as members of
the Corporate Responsibility Committee.



Dr Podolsky's biographical details are given below together with a table showing
the membership of the Board and its Committees with effect from 1st July 2006.





Simon Bicknell
Company Secretary



29 June 2006



Notes



The Board has determined that Dr Podolsky is independent in accordance with the
Combined Code on Corporate Governance.



Biographical details



Dr Daniel Podolsky

Age 53.  Dr Podolsky is a world-renowned researcher who has advanced knowledge
of underlying mechanisms of disease and new therapies for gastrointestinal
disorders. He is also an international authority on trefoil proteins and innate
immunity. Dr. Podolsky has published and patented widely in his field. He is
past editor-in-chief of Gastroenterology, the leading journal in the field, and
is immediate Past President of the American Gastroenterological Association.



Dr Podolsky is also Chairman of the Board & Scientific Co-Founder of the GI
Company a privately held, specialty biopharmaceutical company established to
meet the clinical needs and commercial opportunities available in the field of
gastrointestinal medicine.




                         Board and Committee Membership

                         with effect from 1st July 2006





Sir Christopher Gent                   Chairman

Sir Ian Prosser                        Senior Independent Non-Executive
                                       Director



Dr J-P Garnier                         Chief Executive Officer

Mr J S Heslop                          Chief Financial Officer

Dr Moncef Slaoui                       Executive Director, Chairman, Research &
                                       Development



Dr Daniel Podolsky                     Independent Non-Executive Director

Mr H Lawrence Culp                     Independent Non-Executive Director

Sir Crispin Davis                      Independent Non-Executive Director

Sir Deryck Maughan                     Independent Non-Executive Director

Dr Ronaldo Schmitz                     Independent Non-Executive Director

Mr Tom de Swaan                        Independent Non Executive Director

Sir Robert Wilson                      Independent Non-Executive Director




Board Committee                    Committee Chairman         Members

Audit                              Dr Ronaldo Schmitz*        Sir Deryck Maughan
                                                              Sir Ian Prosser
                                                              Mr Tom de Swaan*
                                                              Sir Robert Wilson


Remuneration                       Sir Robert Wilson          Mr H Lawrence Culp
                                                              Sir Crispin Davis
                                                              Dr Ronaldo Schmitz


Nominations                        Sir Christopher Gent       Sir Ian Prosser
                                                              Dr Ronaldo Schmitz

Corporate Responsibility           Sir Christopher Gent       Sir Ian Prosser
                                                              Mr Tom de Swaan
                                                              Dr Daniel Podolsky



* Mr De Swaan will succeed Dr Schmitz as Chairman of the Audit Committee in
September 2006.




Enquiries:

UK Media enquiries:                  Philip Thomson          [phone]
                                     David Mawdsley          [phone]
                                     Chris Hunter-Ward       [phone]

US Media enquiries:                  Nancy Pekarek           [phone]
                                     Mary Anne Rhyne         [phone]
                                     Patricia Seif           (215)  751 7709

European Analyst/Investor enquiries: Duncan Learmouth        [phone]
                                     Anita Kidgell           [phone]
                                     Jen Hill                [phone]

US Analyst/ Investor enquiries:      Frank Murdolo           [phone]
                                     Tom Curry               [phone]






                      This information is provided by RNS
            The company news service from the London Stock Exchange